Spartha Medical receives €2.4M in financing from European Innovation Council
Spartha Medical receives €2.4M in financing from EIC
Biomunex Pharmaceutical’s breakthrough immunotherapy project receives grants close to €3 Million
Led by Biomunex alongside Institut Curie and GTP Bioways, with a total budget of €5.6 million, BiXAb5 non-conventional T cell redirection project seeks to create breakthrough immunotherapy approach to cancer treatment based on bispecific antibodies
EXCIVA raises €9 Million in series a round led by Andera Partners
German-based startup attracts venture funding from leading European VC firms to address ‘Agitation/Aggression’ in Alzheimer’s disease
GTP Bioways invests € 12M in two GMP biopharmaceutical production units
GTP Bioways strengthens position as leading CDMO in Europe by opening two new biopharmaceutical production units at Toulouse site
GTP Bioways will become the unique CDMO in France with this offer, based on two new lines, one focused on microbial production, the other on small-scale mammalian-based production
ADVENT FRANCE BIOTECHNOLOGY LAUNCHES ITS SECOND FUND WITH A FIRST CLOSE AT €86M ($102M)
• Strong first closing confirms relevance of AFB’s unique early-stage investment strategy; aiming to create, develop and finance promising European life sciences startups in innovative therapeutics
• Since 2017, AFB’s €68M ($80M) first fund – Advent France Biotechnology Seed-Fund I – has successfully financed 15 startups in France, Spain, Belgium and Ireland
New startup aglaia therapeutics raises €4m in seed funding to overcome resistance in oncology targeted therapies
Venture capital firm Advent France Biotechnology led fundraising, alongside Crédit Mutuel Innovation and Pierre Fabre
Co-founded by AFB and leading cancer institutes Gustave Roussy and Institut Curie, startup will use funding to prepare essential preclinical work to identify first oncology program to develop
Advent France Biotechnology crée Thabor Therapeutics et finance son amorçage
Les fonds apportés vont permettre à la nouvelle start-up de développer une approche thérapeutique innovante pour les patients atteints de maladies inflammatoires chroniques
CLEAN CELLS INVESTS OVER €13M IN NEW BIOPHARMACEUTICAL PRODUCTION SITE
